行情

DVAX

DVAX

德纳维制药
NASDAQ

实时行情|Nasdaq Last Sale

6.59
+0.89
+15.61%
已收盘, 18:55 12/09 EST
开盘
5.69
昨收
5.70
最高
6.69
最低
5.65
成交量
315.28万
成交额
--
52周最高
12.42
52周最低
2.595
市值
5.53亿
市盈率(TTM)
-2.7405
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

DVAX 新闻

  • Dynavax up 4% premarket on Albertsons' deal in hepatitis B
  • seekingalpha.4天前
  • Dynavax Technologies Reports Partnership with Alberstons Pharmacies To Offer HEPLISAV-B Vaccine, No Terms Disclosed
  • Benzinga.4天前
  • Dynavax Announces Partnership with Albertsons Companies’ Pharmacies to Offer HEPLISAV-B® Hepatitis B Vaccine to Patients Nationwide
  • GlobeNewswire.4天前
  • Is the Options Market Predicting a Spike in Dynavax (DVAX) Stock?
  • Zacks.6天前

更多

所属板块

生物技术和医学研究
+0.51%
制药与医学研究
+0.23%

热门股票

名称
价格
涨跌幅

DVAX 简况

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma. Its products include HEPLISAV-B, AZD1419, SD-101, DV281, DV230F and DV1001. HEPLISAV-B is an investigational adult hepatitis B vaccine. AZD1419 is being developed for the treatment of asthma. SD-101 is an investigational TLR9 agonist designed to elicit a potent and focused immune response to cancer. DV281 is an investigational TLR9 agonist designed specifically for focused delivery to primary lung tumors and lung metastases. DV230F is indicated for the treatment of Liver Tumors. DV1001 targets TLR 7 and 8 agonist for multiple malignancies. DV230F and DV1001 are in pre-clinical stage of development.
展开

Webull提供Dynavax Technologies Corporation的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。